Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caitlin B Conboy

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Annals of Surgical Oncology|June 26, 2026
The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic CholangiocarcinomaYawen Dong, David Pereyra, Vanja Podrascanin, et al.
Plos One|May 7, 2014
Simple and efficient methods for enrichment and isolation of endonuclease modified cellsBranden S Moriarity, Eric P Rahrmann, Dominic A Beckmann, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2026
Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinomaYawen Dong, David Pereyra, Zhihao Li, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2026
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancerYawen Dong, David Pereyra, Vanja Podrascanin, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 24, 2025
The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytesMuhammed Dogukan Aksu, Jayla T Millender, Chantal E McCabe, et al.
FEBS Open Bio|September 19, 2024
YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escapeRoberto Alva-Ruiz, Ryan D Watkins, Jennifer L Tomlinson, et al.
Annals of Surgical Oncology|May 7, 2026
ASO Visual Abstract: Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic CholangiocarcinomaYawen Dong, Kever A Lewis, David Pereyra, et al.
Annals of Surgical Oncology|May 4, 2026
Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic CholangiocarcinomaYawen Dong, Kever A Lewis, David Pereyra, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaHendrien Kuipers, Danielle M Carlson, Erik Jessen, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Annals of Surgical Oncology|June 26, 2026
The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic CholangiocarcinomaYawen Dong, David Pereyra, Vanja Podrascanin, et al.
Plos One|May 7, 2014
Simple and efficient methods for enrichment and isolation of endonuclease modified cellsBranden S Moriarity, Eric P Rahrmann, Dominic A Beckmann, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2026
Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinomaYawen Dong, David Pereyra, Zhihao Li, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2026
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancerYawen Dong, David Pereyra, Vanja Podrascanin, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 24, 2025
The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytesMuhammed Dogukan Aksu, Jayla T Millender, Chantal E McCabe, et al.
FEBS Open Bio|September 19, 2024
YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escapeRoberto Alva-Ruiz, Ryan D Watkins, Jennifer L Tomlinson, et al.
Annals of Surgical Oncology|May 7, 2026
ASO Visual Abstract: Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic CholangiocarcinomaYawen Dong, Kever A Lewis, David Pereyra, et al.
Annals of Surgical Oncology|May 4, 2026
Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic CholangiocarcinomaYawen Dong, Kever A Lewis, David Pereyra, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaHendrien Kuipers, Danielle M Carlson, Erik Jessen, et al.
Pageof 3